Experience

Davis Polk advised McKesson Corporation on its creation of a new health care information technology company, which will combine substantially all of Change Healthcare Holdings, Inc.’s…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Universal American Corp. of an aggregate principal amount of $115 million of 4.00% convertible senior…

Davis Polk advised the representatives of the underwriters, in connection with an SEC-registered offering by AbbVie Inc. (“AbbVie”) of $7.8 billion aggregate principal amount of senior…

Davis Polk advised the joint book-running managers in connection with an $86.2 million SEC-registered follow-on common stock offering of 8,625,000 shares of common stock for Ardelyx, Inc…

Davis Polk advised Penumbra, Inc. on its SEC-registered initial public offering of 4,600,000 shares of common stock for an aggregate price to the public of approximately $138 million,…

Davis Polk advised the underwriters, in connection with an SEC-registered offering by Seattle Genetics, Inc. of 13,463,415 shares of common stock, which includes 1,756,097 shares of common…

Davis Polk advised the joint book-running managers on an SEC-registered offering by Celgene Corporation of $8.0 billion aggregate principal amount of notes. The notes were issued in…

Davis Polk advised the underwriters in connection with the $72.5 million U.S. initial public offering of 5,175,000 common shares of Cynapsus Therapeutics Inc., including 675,000 common…

Davis Polk is advising Bio-Reference Laboratories, Inc. in connection with its approximately $1.47 billion acquisition by OPKO Health, Inc. Under the terms of the agreement, holders of Bio…

Davis Polk advised the joint book-running managers and representatives of the underwriters on a public offering by Laboratory Corporation of America Holdings (LabCorp) of $500 million…